Uncover key drivers, emerging technologies, and competitive movements shaping the cell therapy bioreactors market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Antimicrobial Resistance Diagnostics Market be in 2030 compared with 2026?

The size of the antimicrobial resistance diagnostics market has experienced robust growth over recent years. This market is projected to expand from $4.41 billion in 2025 to $4.74 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historically, this growth has been driven by factors such as the increasing spread of antibiotic-resistant infections, the widespread use of traditional culture-based diagnostic methods, an uptick in hospital-acquired infections, a heightened understanding of antimicrobial stewardship, and the proliferation of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market is anticipated to experience substantial expansion over the coming years, reaching $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth is driven by several factors, including advancements in PCR and NGS diagnostic technologies, an increase in government funding allocated to AMR surveillance initiatives, the growing acceptance of rapid diagnostic tests, an expansion in pharmaceutical and biotechnology research, and the incorporation of data-driven decision support tools. Key trends shaping the forecast period involve a rising uptake of rapid and point-of-care antimicrobial resistance diagnostics, an increasing need for targeted and personalized antimicrobial treatments, enhanced monitoring of drug-resistant pathogens, the broadening of molecular and genomic diagnostic testing, and the reinforcement of hospital infection control and stewardship strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

What Drivers Are Guiding Growth Patterns In The Antimicrobial Resistance Diagnostics Market?

The increasing occurrence of drug-resistant infections is anticipated to boost the expansion of the antimicrobial resistance diagnostics market in the future. These infections develop when microbes such as bacteria, viruses, fungi, or parasites acquire ways to withstand drugs that previously worked, rendering conventional treatments useless and infections more challenging to manage. The expanding presence of drug-resistant infections stems from the excessive use of antibiotics in farming, where small amounts of antimicrobials are regularly incorporated into animal feed, fostering resistance capable of transmitting to humans via the food chain. Tools like rapid genetic assays and culture-based sensitivity tests within antimicrobial resistance diagnostics are crucial in countering the rising incidence of drug-resistant infections, as they facilitate prompt detection of resistant disease-causing agents, direct specific treatments, and decrease the inappropriate use of wide-ranging antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a government body in the UK, stated that serious antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023, concurrently with antibiotic use growing to 2.4% in 2023 from 2022. Consequently, the increasing occurrence of drug-resistant infections is propelling the growth of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Divided Into Segments?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Influencing The Performance And Direction Of The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance (AMR) diagnostics market are increasingly leveraging innovative technologies, such as point-of-care antimicrobial-susceptibility testing (AST) solutions, to boost diagnostic speed, precision, and antimicrobial-stewardship outcomes. Point-of-care antimicrobial-susceptibility testing (AST) involves rapid, near-patient analyses that pinpoint which antibiotics will be effective against an infection, thereby assisting clinicians in quickly selecting targeted and successful treatments. For instance, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, launched its PA-100 AST System, a point-of-care rapid AST platform designed to detect bacterial presence and determine antimicrobial susceptibility in urine samples within approximately 30 minutes. This system incorporates features such as microfluidic single-cell analysis, near-patient testing capabilities, and automated reporting of susceptibility results. The PA-100 AST System thereby improves clinical decision-making, reduces unnecessary antibiotic prescriptions, and supports timely, targeted therapy to combat antimicrobial resistance.

Which Leading Companies Dominate The Antimicrobial Resistance Diagnostics Market Share?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

How Does The Antimicrobial Resistance Diagnostics Market Perform Across Major Global Regions?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antimicrobial Resistance Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company